Funding Opportunity PAS-22-207 from the NIH Guide for Grants and Contracts. This HEAL FOA provides an opportunity for early career researchers or early career clinicians with foundational backgrounds in addiction to develop expertise in implementation science. Successful applicants would propose training in implementation science methods, and a research project that would apply these to at least one of the four priority domains of the HHS Overdose Prevention Strategy: primary prevention (including appropriate opioid prescribing), OUD treatment, harm reduction, and/or recovery support services. The overarching goal is to build a cadre of implementation researchers who can contribute to addressing the current overdose crisis, develop research careers that will impact the quality of addiction clinical practice generally, and become the next generation of implementation experts and mentors.

Funding Opportunity PAR-22-216 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).

Notice NOT-OD-22-184 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-178 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-179 from the NIH Guide for Grants and Contracts

Notice NOT-DA-23-011 from the NIH Guide for Grants and Contracts

This will involve mastering basic statistics (correlation analysis, ANOVA, ANCOVA, principal components), implementation of R-code for genetic quantitativetrait… $58,000 a year
From University of Wisconsin–Madison - Thu, 14 Jul 2022 00:57:26 GMT - View all Madison, WI jobs

£19.08phr (PAYE) £26.02phr (Umb): CK Group: CK Group are recruiting for a Bioinformatician to join a global pharmaceutical company, based in Slough on a contract basis initially for 9 months Salary: ... Slough

Competitive Salary: F. Hoffmann-La Roche AG: Roche Sequencing Solutions (RSS), a business within Roche Diagnostics, is focused on developing a disruptive Next-Generation Sequencing (NGS) platform United States (US)

Competitive Salary: F. Hoffmann-La Roche AG: The PositionThis position may be based out of Santa Clara, CA, USA, with remote work locations possible in The United States.Impact HealthcareRoche Se Santa Clara, California (US)

Notice NOT-OD-22-183 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-TR-22-029 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease. To facilitate clinical trial start up, and leverage existing datasets, preference will be given to applications focusing on diseases that are under study by the Rare Disease Clinical Research Network (RDCRN), and that involve collaborations with RDCRN clinical investigators.

Funding Opportunity RFA-DK-22-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).

Notice NOT-CA-22-096 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-097 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-098 from the NIH Guide for Grants and Contracts

Notice NOT-MH-22-175 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AT-23-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to support multisite efficacy or effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management, allowing continued opioid pain management as needed. However, opioid medication use alone should not be the only intervention studied. Trials supported under this initiative may also address the impact of these approaches on related psychological and functional outcomes to support improved overall well-being and quality of life. In addition, studies that address stigma, structural health care system, and social factors that may hinder quality comprehensive pain care for patients with SCD are also of interest. Investigators are encouraged to include the collection of well-justified biological markers or psychological processes that have demonstrated that they may mediate pain outcomes. Trials should collect sufficient measures to phenotypeclinically characterize participants such as type of pain, variability of pain, co-occurring conditions, and social determinants of health. The studies must address questions within the mission and research interests of the NIH HEAL Initiative and evaluate preventive or treatment strategies or interventions including medications, biologics, procedures, medical and assistive devices and technologies, behavioral interventions, rehabilitation strategies, complementary interventions, integrated approaches, and delivery system strategies in well controlled trials in patients with SCD to manage acute and/or chronic pain.

Funding Opportunity RFA-AT-23-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit cooperative agreement applications to conduct multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic sickle cell disease (SCD) pain management in health care systems that serve the SCD population. Trials may include or allow continuation of opioid medication as needed; however opioid medication use alone should not be the only intervention studied. Trials may propose methods to implement, improve adherence, or evaluate the effectiveness of guidelines for pain management in patients with SCD in various health care settings. Trials supported under this initiative could also address social and structural barriers such as stigma and racial bias to SCD pain management care.

Notice NOT-HD-22-029 from the NIH Guide for Grants and Contracts